See more : Glantus Holdings PLC (GLAN.L) Income Statement Analysis – Financial Results
Complete financial analysis of Hemogenyx Pharmaceuticals Plc (HOPHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hemogenyx Pharmaceuticals Plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Aurubis AG (AIAGY) Income Statement Analysis – Financial Results
- Motorsport Games Inc. (MSGM) Income Statement Analysis – Financial Results
- Themis Medicare Limited (THEMISMED.BO) Income Statement Analysis – Financial Results
- PennantPark Floating Rate Capital Ltd. (PFLT) Income Statement Analysis – Financial Results
- Kaufman & Broad S.A. (KOF.PA) Income Statement Analysis – Financial Results
Hemogenyx Pharmaceuticals Plc (HOPHF)
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.85K | 0.00 |
| Cost of Revenue | 645.68K | 2.60M | 283.65K | 350.72K | 421.82K | 348.27K | 100.48K | 66.86K | 0.00 | 0.00 |
| Gross Profit | -645.68K | -2.60M | -283.65K | -350.72K | -421.82K | -348.27K | -100.48K | -66.86K | 6.85K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 90.63K | 487.10 | 50.82 | 114.41 | 28.14 | 73.50 | 18.96 | 2.00 | 0.00 | 0.00 |
| General & Administrative | 4.91M | 942.35K | 1.40M | 623.84K | 429.07K | 402.98K | 390.66K | 331.59K | 174.30K | 6.27K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 4.22K | 33.51K | 14.63K | 19.49K | 80.40K | 3.54 | 0.00 |
| SG&A | 4.91M | 942.35K | 1.40M | 628.06K | 462.58K | 417.61K | 410.16K | 411.99K | 176.70K | 6.27K |
| Other Expenses | 1.46M | 0.00 | 0.00 | 85.24K | 213.13K | 91.36K | 101.14K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.47M | 2.93M | 2.55M | 1.87M | 1.25M | 1.26M | 690.69K | 411.99K | 176.70K | 6.27K |
| Cost & Expenses | 6.47M | 5.53M | 2.83M | 2.22M | 1.67M | 1.61M | 791.17K | 411.99K | 176.70K | 6.27K |
| Interest Income | 85.34K | 10.60K | 17.96K | 3.37K | 14.19K | 4.37K | 14.50 | 14.56 | 16.25 | 0.00 |
| Interest Expense | 315.99K | 33.00 | 2.60M | 33.24K | 31.33K | 1.78K | 10.74K | 11.82K | 0.00 | 0.00 |
| Depreciation & Amortization | 225.40K | 564.07K | 126.34K | 106.75K | 94.73K | 51.81K | 33.61K | 11.87K | 169.86K | 0.00 |
| EBITDA | -5.33M | -5.44M | -2.56M | -2.08M | -1.63M | -1.63M | -837.06K | -447.15K | -0.59 | -6.27K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -160.97% | 0.00% |
| Operating Income | -6.47M | 4.00M | -2.70M | -2.15M | -1.68M | -1.62M | -820.98K | -519.90K | -169.86K | -6.27K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,481.32% | 0.00% |
| Total Other Income/Expenses | -230.65K | 10.57K | -2.41M | 55.36K | 195.99K | 27.16K | -1.49M | -11.82K | -11.02K | 0.00 |
| Income Before Tax | -6.70M | -3.99M | -5.11M | -2.10M | -1.49M | -1.52M | -2.36M | -519.90K | -180.88K | -6.27K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,642.29% | 0.00% |
| Income Tax Expense | 0.00 | 361.20K | 2.41M | 20.51K | -35.00K | -43.75K | 67.10 | 215.78K | -16.25 | 0.00 |
| Net Income | -6.69M | -3.98M | -5.10M | -2.08M | -1.45M | -1.48M | -2.36M | -519.90K | -180.88K | -6.27K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,642.29% | 0.00% |
| EPS | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 1.13B | 979.75M | 773.95M | 414.83M | 360.72M | 360.13M | 260.27M | 145.17M | 12.66M | 64.90M |
| Weighted Avg Shares Out (Dil) | 1.13B | 979.75M | 773.95M | 414.83M | 360.72M | 360.13M | 260.27M | 145.17M | 12.66M | 64.90M |
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise US$4.2 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE...
Hemogenyx Pharmaceuticals PLC Announces CBR Brain Delivery
Chimeric Bait Receptors for Combatting Brain Cancers and Neurodegenerative Diseases Can Be Delivered via Programmed Microglial Cells LONDON, UK / ACCESSWIRE / February 16, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical stage biopharmaceutical group, announces that it has demonstrated...
Hemogenyx shares jump 16% on nasal delivery news
Shares in HemoGenyx Pharmaceuticals (LSE:HEMO) PLC rose 16% following the announcement that its chimeric bait receptor (CBR) technology for combatting airborne viral infections can be delivered intranasally using messenger RNA (mRNA). In the lab it was able to demonstrate that mRNA...
Hemogenyx Pharmaceuticals PLC Announces CBR Intranasal Delivery
Chimeric Bait Receptors for Combatting Airborne Viral Infections Can Be Delivered Intranasally LONDON, UK / ACCESSWIRE / February 14, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO),the clinical stage biopharmaceutical group,announces that it has demonstrated in vivo that its proprietary Chimeric Bait...
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T
FDA Consents to Phase I Trials of HEMO-CAR-T LONDON, UK / ACCESSWIRE / February 9, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has been informed by the U.S. Federal Food and Drug Administration ("FDA") that...
Hemogenyx Pharmaceuticals gets extra US patent protection for CDX
HemoGenyx Pharmaceuticals (LSE:HEMO) PLC said a "significant" application made with the United States Patent and Trademark Office has been approved to protect its CDX antibody technology. The patent application was entitled 'Method of Eliminating Hematopoietic Stem Cells/Hematopoietic Progenitors (HSC/HP) In A Patient...
Hemogenyx Pharmaceuticals PLC Announces the Approval and Issuance of U.S. Conditioning Patent
Approval and Issuance of U.S. Conditioning Patent LONDON, UK / ACCESSWIRE / February 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that a patent application entitledMethod of Eliminating Hematopoietic Stem Cells/Hematopoietic Progenitors (HSC/HP) In A Patient Using...
Hemogenyx Pharmaceuticals PLC Announces Submission of Complete Response to Clinical Hold
Submission of Complete Response to Clinical Hold for HEMO-CAR-T IND LONDON, UK / ACCESSWIRE / January 16, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces the submission of a complete response tothe previously announced Clinical Hold ("CH") of the Investigational New...
Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Process Qualification Run Completed
LONDON, UK / ACCESSWIRE / January 8, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), which is developing new therapies and treatments for blood diseases, is pleased to announce the successful completion of its Process Qualification ("PQ") run of the end-to-end process...
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £534,375
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE...
Source: https://incomestatements.info
Category: Stock Reports